



10069,242
PCT/GB 00/03424



INVESTOR IN PEOPLE

BEST AVAILABLE COPY

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


| |
|-------------------|
| REC'D 18 OCT 2000 |
| WIPO PCT |

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *A. B. Jones*


Dated 2 October 2000

The
Patent
Office

1/77
07SEP99 14:15 D02884
P01/7700 0:00 9920974.4

Request for grant of a patent

See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference P23064/PKE/BOU

2. Patent application number 9920974.4 -7 SEP 1999
(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)
Giltech Limited
9/12 North Harbour Estate
AYR
KA8 8AA

Patents ADP number (if you know it)

40/5822002 TS

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention "Growth Substrate"

5. Name of your agent (if you have one) Murgitroyd & Company
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)
373 Scotland Street
GLASGOW
G5 8QA

Patents ADP number (if you know it) 1198013

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

| Country | Priority application number (if you know it) | Date of filing (day / month / year) |
|---------|--|-------------------------------------|
| - | - | - |

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

| Number of earlier application | Date of filing (day / month / year) |
|-------------------------------|-------------------------------------|
| - | - |

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 6.9.1999

Murgitroyd & Company

12. Name and daytime telephone number of person to contact in the United Kingdom

Beverley Ouzman

0141 307 8400

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

S.H.Cartmell, P.J.Doherty, C.C.M.Thompson*, D.Ilealy*, T.Gilchrist*

Dept. of Clinical Engineering, University Of Liverpool, Daulby Street, Liverpool L69 3GA U.K.

*Department of Vet. Clin. Sci., University Of Liverpool U.K.

*Giltech Ltd., 8-12 North Harbour Estate, Ayr KA8 8AA U.K.

INTRODUCTION

Controlled Release Glass (CRG) is a phosphate based material which degrades at a predeterminable rate. The potential for using CRG as a cartilage engineering matrix has been assessed using isolated equine chondrocytes with *in-vitro* techniques. The glass was provided in fibrous form in three different compositions by Giltech Ltd.. The three CRG compositions provided have showed potential as a tissue engineering substrate.

MATERIALS AND METHOD

A total of 200,000 chondrocytes isolated from horse articular cartilage were added to each 2cm well in a 24 well plate. Every well contained 0.02grams of glass fibre sample. Four different fibres (diameters 20-30 μ m) were analysed: F1 - containing Fe₂O₃ and NaF, F2 - containing Ce₂O₃ and F3 - containing Ce₂O₃ and Se. The culture medium (containing 10% FCS) was changed daily. At time periods of 3 days, 1 week and 2 weeks, the samples were stained using rhodamine phalloidin and oregon green for the viewing of actin and tubulin using a laser scanning confocal microscope. At the same time periods, the cell supernatant was removed and stored at -80°C until analysis on cell viability and type II collagen production could be performed. Production of type II collagen was analysed by using RT-PCR analysis on the cDNA from the chondrocyte population in contact with the glass fibres. The total RNA was prepared from the cell population by the addition of 1ml of TRIzol (SIGMA) to the cell population for 5 minutes. After this time, The TRIzol was retrieved and stored at -80°C until RT-PCR analysis could be carried out. The RT-PCR analysis was performed by tagging with primers for collagen type II and with gapDH for cell viability. Zymography was also performed at time periods of 4 days, 1 week and 2 weeks for

detection of matrix metalloproteinases (MMP's) produced by the chondrocytes.

RESULTS AND CONCLUSIONS

Chondrocytes adhered to all three types of fibre sample. At the 3 day time period, the cells appeared to be rounded. At 1 week and 2 weeks, confocal microscopy indicated cell proliferation between all time periods. At 1 week and 2 weeks, the cells were elongated and formed a monolayer along the fibre length as can be seen in Figure 1.

The RT-PCR analysis showed that fibres F2 and F3 were producing collagen type II up to and including the two week time period indicating that the cells retained their chondrocytic phenotype.

The zymography performed on F2 and F3, showed that the cells in contact with these fibres produced MMP2 at all three time periods, but in a greater quantity at 2 weeks than 1 week, and at 1 week than 4 days. This increase of MMP2 production is expected, as the cells were seen to have increased in number at these time periods from the confocal microscope analysis.

In conclusion, all three fibres types showed cell adherence and the chondrocytes adhered to F2 and F3 appear to retain the ability to produce type II collagen.




Figure 1. Adhered chondrocytes to fibre F1 at 2 weeks.

The authors wish to acknowledge the EPSRC for funding of this work.

"GROWTH SUBSTRATE"

S.H.Cartmell, P.J.Doherty, C.C.M.Thompson*, D.Healy*, T.Gilchrist*

Dept. of Clinical Engineering, University Of Liverpool, Daulby Street, Liverpool L69 3GA U.K.

*Department of Vet. Clin. Sci., University Of Liverpool U.K.

*Giltech Ltd., 8-12 North Harbour Estate, Ayr KA8 8AA U.K.

INTRODUCTION

Controlled Release Glass (CRG) is a phosphate based material which degrades at a predeterminable rate. The potential for using CRG as a cartilage engineering matrix has been assessed using isolated equine chondrocytes with *in-vitro* techniques. The glass was provided in fibrous form in three different compositions by Giltech Ltd.. The three CRG compositions provided have showed potential as a tissue engineering substrate.

MATERIALS AND METHOD

A total of 200,000 chondrocytes isolated from horse articular cartilage were added to each 2cm well in a 24 well plate. Every well contained 0.02grams of glass fibre sample. Four different fibres (diameters 20-30µm) were analysed: F1 - containing Fe_2O_3 and NaF, F2 - containing Ce_2O_3 and F3 - containing Ce_2O_3 and Se. The culture medium (containing 10% FCS) was changed daily. At time periods of 3 days, 1 week and 2 weeks, the samples were stained using rhodamine phalloidin and oregon green for the viewing of actin and tubulin using a laser scanning confocal microscope. At the same time periods, the cell supernatant was removed and stored at $-80^{\circ}C$ until analysis on cell viability and type II collagen production could be performed. Production of type II collagen was analysed by using RT-PCR analysis on the cDNA from the chondrocyte population in contact with the glass fibres. The total RNA was prepared from the cell population by the addition of 1ml of TRIzol (SIGMA) to the cell population for 5 minutes. After this time, The TRIzol was retrieved and stored at $-80^{\circ}C$ until RT-PCR analysis could be carried out. The RT-PCR analysis was performed by tagging with primers for collagen type II and with gapDH for cell viability.

Zymography was also performed at time periods of 4 days, 1 week and 2 weeks for

detection of matrix metalloproteinases (MMP's) produced by the chondrocytes.

RESULTS AND CONCLUSIONS

Chondrocytes adhered to all three types of fibre sample. At the 3 day time period, the cells appeared to be rounded. At 1 week and 2 weeks, confocal microscopy indicated cell proliferation between all time periods. At 1 week and 2 weeks, the cells were elongated and formed a monolayer along the fibre length as can be seen in Figure 1.

The RT-PCR analysis showed that fibres F2 and F3 were producing collagen type II up to and including the two week time period indicating that the cells retained their chondrocytic phenotype.

The zymography performed on F2 and F3, showed that the cells in contact with these fibres produced MMP2 at all three time periods, but in a greater quantity at 2 weeks than 1 week, and at 1 week than 4 days. This increase of MMP2 production is expected, as the cells were seen to have increased in number at these time periods from the confocal microscope analysis.

In conclusion, all three fibres types showed cell adherence and the chondrocytes adhered to F2 and F3 appear to retain the ability to produce type II collagen.



Figure 1. Adhered chondrocytes to fibre F1 at 2 weeks.

The authors wish to acknowledge the EPSRC for funding of this work.

PCT/213 00/0 3424

4-9-00

mutgilewyd & company

GB0003424

